全文获取类型
收费全文 | 2478155篇 |
免费 | 180384篇 |
国内免费 | 3837篇 |
专业分类
耳鼻咽喉 | 33587篇 |
儿科学 | 79166篇 |
妇产科学 | 64896篇 |
基础医学 | 365009篇 |
口腔科学 | 66688篇 |
临床医学 | 224649篇 |
内科学 | 483458篇 |
皮肤病学 | 54423篇 |
神经病学 | 197438篇 |
特种医学 | 93622篇 |
外国民族医学 | 501篇 |
外科学 | 373540篇 |
综合类 | 49199篇 |
现状与发展 | 12篇 |
一般理论 | 944篇 |
预防医学 | 192775篇 |
眼科学 | 56976篇 |
药学 | 183650篇 |
11篇 | |
中国医学 | 4788篇 |
肿瘤学 | 137044篇 |
出版年
2021年 | 21673篇 |
2019年 | 22031篇 |
2018年 | 29995篇 |
2017年 | 22619篇 |
2016年 | 25294篇 |
2015年 | 28470篇 |
2014年 | 40033篇 |
2013年 | 59507篇 |
2012年 | 82881篇 |
2011年 | 88138篇 |
2010年 | 52173篇 |
2009年 | 49408篇 |
2008年 | 82459篇 |
2007年 | 87665篇 |
2006年 | 88393篇 |
2005年 | 85830篇 |
2004年 | 81798篇 |
2003年 | 78568篇 |
2002年 | 76004篇 |
2001年 | 110423篇 |
2000年 | 112825篇 |
1999年 | 95170篇 |
1998年 | 28519篇 |
1997年 | 24922篇 |
1996年 | 25138篇 |
1995年 | 23726篇 |
1994年 | 21772篇 |
1993年 | 20548篇 |
1992年 | 73098篇 |
1991年 | 71038篇 |
1990年 | 69257篇 |
1989年 | 66457篇 |
1988年 | 61134篇 |
1987年 | 59853篇 |
1986年 | 55990篇 |
1985年 | 53744篇 |
1984年 | 40092篇 |
1983年 | 34111篇 |
1982年 | 20628篇 |
1979年 | 36459篇 |
1978年 | 26210篇 |
1977年 | 21697篇 |
1976年 | 20795篇 |
1975年 | 22215篇 |
1974年 | 26606篇 |
1973年 | 25214篇 |
1972年 | 23589篇 |
1971年 | 22334篇 |
1970年 | 20551篇 |
1969年 | 19548篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
961.
962.
Mahnaz Fatahzadeh Lida Radfar David A Sirois 《Quintessence international, dental digest》2006,37(10):777-787
Dental management of patients with autoimmune vesiculobullous disorders is complicated because of prominent involvement of oral mucosa, increased risk of oral disease, and difficulty in rendering dental care. Although these diseases are relatively uncommon, dental practitioners should be familiar with the oral sequelae of these conditions and their management. Pemphigus vulgaris, cicatricial pemphigoid, and epidermolysis bullosa represent the most common autoimmune oral vesiculobullous diseases. This case-illustrated review summarizes the pathogenesis, diagnostic features, and natural history of oral vesiculobullous disorders, placing an emphasis on the treatment and prevention of associated oral disease aimed at maintaining a healthy, functional dentition. 相似文献
963.
964.
Yubin Miao Said D Figueroa Darrell R Fisher Herbert A Moore Richard F Testa Timothy J Hoffman Thomas P Quinn 《Journal of nuclear medicine》2008,49(5):823-829
Peptide-targeted alpha-therapy with 7.4 MBq of (212)Pb-[1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-ReO-[Cys(3,4,10),d-Phe(7),Arg(11)]alpha-MSH(3-13) ((212)Pb-DOTA-Re(Arg(11))CCMSH) cured 45% of B16/F1 murine melanoma-bearing C57 mice in a 120-d study, highlighting its melanoma treatment potential. However, there is a need to develop an imaging surrogate for patient-specific dosimetry and to monitor the tumor response to (212)Pb-DOTA-Re(Arg(11))CCMSH therapy. The purpose of this study was to evaluate the potential of (203)Pb-DOTA-Re(Arg(11))CCMSH as a matched-pair SPECT agent for (212)Pb-DOTA-Re(Arg(11))CCMSH. METHODS: DOTA-Re(Arg(11))CCMSH was labeled with (203)Pb in 0.5 M NH(4)OAc buffer at pH 5.4. The internalization and efflux of (203)Pb-DOTA-Re(Arg(11))CCMSH were determined in B16/F1 melanoma cells. The pharmacokinetics of (203)Pb-DOTA-Re(Arg(11))CCMSH was examined in B16/F1 melanoma-bearing C57 mice. A micro-SPECT/CT study was performed with (203)Pb-DOTA-Re(Arg(11))CCMSH in a B16/F1 melanoma-bearing C57 mouse at 2 h after injection. RESULTS: (203)Pb-DOTA-Re(Arg(11))CCMSH was easily prepared in NH(4)OAc buffer and completely separated from the excess nonradiolabeled peptide by reversed-phase high-performance liquid chromatography (RP-HPLC). (203)Pb-DOTA-Re(Arg(11))CCMSH displayed fast internalization and extended retention in B16/F1 cells. Approximately 73% of (203)Pb-DOTA-Re(Arg(11))CCMSH activity internalized after a 20-min incubation at 25 degrees C. After incubation of the cells in culture medium for 20 min, 78% of internalized activity remained in the cells. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a biodistribution pattern similar to that of (212)Pb-DOTA-Re(Arg(11))CCMSH in B16/F1 melanoma-bearing mice. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a peak tumor uptake of 12.00+/-3.20 percentage injected dose per gram (%ID/g) at 1 h after injection. The tumor uptake gradually decreased to 3.43+/-1.12 %ID/g at 48 h after injection. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a peak tumor-to-kidney uptake ratio of 1.53 at 2 h after injection. The absorbed doses to the tumor and kidneys were 4.32 and 4.35 Gy, respectively, per 37 MBq. Whole-body clearance of (203)Pb-DOTA-Re(Arg(11))CCMSH was fast, with approximately 89% of the injected activity cleared through the urinary system by 2 h after injection. (203)Pb showed 1.6-mm SPECT resolution, which was comparable to (99m)Tc. Melanoma lesions were visualized through SPECT/CT images of (203)Pb-DOTA-Re(Arg(11))CCMSH at 2 h after injection. CONCLUSION: (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited favorable pharmacokinetic and tumor imaging properties, highlighting its potential as a matched-pair SPECT agent for (212)Pb-DOTA-Re(Arg(11))CCMSH melanoma treatment. 相似文献
965.
966.
967.
968.
969.
970.
ngela P. de Mattos Tereza C.M. Ribeiro Patrícia S.A. Mendes Sandra S. Valois Carlos M.C. Mendes Hugo C. Ribeiro Jr 《Nutrition Research》2009,29(7):462-469
Although previous studies have shown successful treatment of persistent diarrhea (PD) with the use of yogurt-based diets, some recent ones speculate the need of special formulas for the nutritional management of PD complicated cases. In the present study, we tested the hypothesis that the consumption of 3 lactose-free diets, with different degrees of complexity, is associated with lower stool output and shorter duration of diarrhea when compared with the use of a yogurt-based one on the nutritional management of PD. A total of 154 male infants, aged between 1 and 30 months, with PD and with or without dehydration, were randomly assigned to 1 of 4 treatment groups. Throughout the study, the patients were placed in a metabolic unit; their body weights and intakes of oral rehydration solution, water, and formula diets, in addition to outputs of stool, urine, and vomit, were measured and recorded at 24-hour intervals. Four different diets were used in this study: diet 1, yogurt-based formula; diet 2, soy-based formula; diet 3, hydrolyzed protein-based formula; and diet 4, amino acid–based formula. Throughout the study, only these formula diets were fed to the children. The data showed that children fed the yogurt-based diet (diet 1) or the amino acid–based diet (diet 4) had a significant reduction in stool output and in the duration of diarrhea. The use of an inexpensive and worldwide-available yogurt-based diet is recommended as the first choice for the nutritional management of mild to moderate PD. For the few complicated PD cases, when available, a more complex amino acid–based diet should be reserved for the nutritional management of these unresponsive and severe presentations. Soy-based or casein-based diets do not offer any specific advantage or benefits and do not seem to have a place in the management of PD. 相似文献